Oligomeric tau-targeted immunotherapy in Tg4510 mice

Sulana Schroeder, Aurelie Joly-Amado, Ahlam Soliman, Urmi Sengupta, Rakez Kayed, Marcia N. Gordon, David Morgan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer's disease and other tauopathies. Immunotherapy against tau has shown promise in several mouse models. In particular, an antibody with selectivity for oligomeric forms of tau, tau oligomer monoclonal antibody (TOMA), has shown rescue of the behavioral phenotype in several murine models of tau deposition. Methods: In this study, we examined the capacity of TOMA to rescue the behavioral, histological, and neurochemical consequences of tau deposition in the aggressive Tg4510 model. We treated mice biweekly with 60 μg TOMA i.p. from 3.5 to 8 months of age. Results: Near the end of the treatment, we found that oligomeric tau was elevated in both the CSF and in plasma. Further, we could detect mouse IgG in Tg4510 mouse brain after TOMA treatment, but not after injection with mouse IgG1 as control. However, we did not find significant reductions in behavioral deficits or tau deposits by either histological or biochemical measurements. Conclusions: These data suggest that there is some exposure of the Tg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these mice at the doses used. These data are consistent with other observations that the rapidly depositing Tg4510 mouse is a challenging model in which to demonstrate efficacy of tau-lowering treatments compared to some other preclinical models of tau deposition/overexpression.

Original languageEnglish (US)
Article number46
JournalAlzheimer's Research and Therapy
Volume9
Issue number1
DOIs
StatePublished - Jun 27 2017

Fingerprint

Immunotherapy
Monoclonal Antibodies
Brain
Immunoglobulin G
Tauopathies
Phenotype
Therapeutics
Alzheimer Disease
Injections
Antibodies

Keywords

  • Immunotherapy
  • Oligomers
  • Tau
  • Tg4510 mouse

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Schroeder, S., Joly-Amado, A., Soliman, A., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017). Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's Research and Therapy, 9(1), [46]. https://doi.org/10.1186/s13195-017-0274-6

Oligomeric tau-targeted immunotherapy in Tg4510 mice. / Schroeder, Sulana; Joly-Amado, Aurelie; Soliman, Ahlam; Sengupta, Urmi; Kayed, Rakez; Gordon, Marcia N.; Morgan, David.

In: Alzheimer's Research and Therapy, Vol. 9, No. 1, 46, 27.06.2017.

Research output: Contribution to journalArticle

Schroeder, S, Joly-Amado, A, Soliman, A, Sengupta, U, Kayed, R, Gordon, MN & Morgan, D 2017, 'Oligomeric tau-targeted immunotherapy in Tg4510 mice', Alzheimer's Research and Therapy, vol. 9, no. 1, 46. https://doi.org/10.1186/s13195-017-0274-6
Schroeder S, Joly-Amado A, Soliman A, Sengupta U, Kayed R, Gordon MN et al. Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's Research and Therapy. 2017 Jun 27;9(1). 46. https://doi.org/10.1186/s13195-017-0274-6
Schroeder, Sulana ; Joly-Amado, Aurelie ; Soliman, Ahlam ; Sengupta, Urmi ; Kayed, Rakez ; Gordon, Marcia N. ; Morgan, David. / Oligomeric tau-targeted immunotherapy in Tg4510 mice. In: Alzheimer's Research and Therapy. 2017 ; Vol. 9, No. 1.
@article{a2f6649ecfaf4f078104ab4f99a9e808,
title = "Oligomeric tau-targeted immunotherapy in Tg4510 mice",
abstract = "Background: Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer's disease and other tauopathies. Immunotherapy against tau has shown promise in several mouse models. In particular, an antibody with selectivity for oligomeric forms of tau, tau oligomer monoclonal antibody (TOMA), has shown rescue of the behavioral phenotype in several murine models of tau deposition. Methods: In this study, we examined the capacity of TOMA to rescue the behavioral, histological, and neurochemical consequences of tau deposition in the aggressive Tg4510 model. We treated mice biweekly with 60 μg TOMA i.p. from 3.5 to 8 months of age. Results: Near the end of the treatment, we found that oligomeric tau was elevated in both the CSF and in plasma. Further, we could detect mouse IgG in Tg4510 mouse brain after TOMA treatment, but not after injection with mouse IgG1 as control. However, we did not find significant reductions in behavioral deficits or tau deposits by either histological or biochemical measurements. Conclusions: These data suggest that there is some exposure of the Tg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these mice at the doses used. These data are consistent with other observations that the rapidly depositing Tg4510 mouse is a challenging model in which to demonstrate efficacy of tau-lowering treatments compared to some other preclinical models of tau deposition/overexpression.",
keywords = "Immunotherapy, Oligomers, Tau, Tg4510 mouse",
author = "Sulana Schroeder and Aurelie Joly-Amado and Ahlam Soliman and Urmi Sengupta and Rakez Kayed and Gordon, {Marcia N.} and David Morgan",
year = "2017",
month = "6",
day = "27",
doi = "10.1186/s13195-017-0274-6",
language = "English (US)",
volume = "9",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Oligomeric tau-targeted immunotherapy in Tg4510 mice

AU - Schroeder, Sulana

AU - Joly-Amado, Aurelie

AU - Soliman, Ahlam

AU - Sengupta, Urmi

AU - Kayed, Rakez

AU - Gordon, Marcia N.

AU - Morgan, David

PY - 2017/6/27

Y1 - 2017/6/27

N2 - Background: Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer's disease and other tauopathies. Immunotherapy against tau has shown promise in several mouse models. In particular, an antibody with selectivity for oligomeric forms of tau, tau oligomer monoclonal antibody (TOMA), has shown rescue of the behavioral phenotype in several murine models of tau deposition. Methods: In this study, we examined the capacity of TOMA to rescue the behavioral, histological, and neurochemical consequences of tau deposition in the aggressive Tg4510 model. We treated mice biweekly with 60 μg TOMA i.p. from 3.5 to 8 months of age. Results: Near the end of the treatment, we found that oligomeric tau was elevated in both the CSF and in plasma. Further, we could detect mouse IgG in Tg4510 mouse brain after TOMA treatment, but not after injection with mouse IgG1 as control. However, we did not find significant reductions in behavioral deficits or tau deposits by either histological or biochemical measurements. Conclusions: These data suggest that there is some exposure of the Tg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these mice at the doses used. These data are consistent with other observations that the rapidly depositing Tg4510 mouse is a challenging model in which to demonstrate efficacy of tau-lowering treatments compared to some other preclinical models of tau deposition/overexpression.

AB - Background: Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer's disease and other tauopathies. Immunotherapy against tau has shown promise in several mouse models. In particular, an antibody with selectivity for oligomeric forms of tau, tau oligomer monoclonal antibody (TOMA), has shown rescue of the behavioral phenotype in several murine models of tau deposition. Methods: In this study, we examined the capacity of TOMA to rescue the behavioral, histological, and neurochemical consequences of tau deposition in the aggressive Tg4510 model. We treated mice biweekly with 60 μg TOMA i.p. from 3.5 to 8 months of age. Results: Near the end of the treatment, we found that oligomeric tau was elevated in both the CSF and in plasma. Further, we could detect mouse IgG in Tg4510 mouse brain after TOMA treatment, but not after injection with mouse IgG1 as control. However, we did not find significant reductions in behavioral deficits or tau deposits by either histological or biochemical measurements. Conclusions: These data suggest that there is some exposure of the Tg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these mice at the doses used. These data are consistent with other observations that the rapidly depositing Tg4510 mouse is a challenging model in which to demonstrate efficacy of tau-lowering treatments compared to some other preclinical models of tau deposition/overexpression.

KW - Immunotherapy

KW - Oligomers

KW - Tau

KW - Tg4510 mouse

UR - http://www.scopus.com/inward/record.url?scp=85021304548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021304548&partnerID=8YFLogxK

U2 - 10.1186/s13195-017-0274-6

DO - 10.1186/s13195-017-0274-6

M3 - Article

C2 - 28655349

AN - SCOPUS:85021304548

VL - 9

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 46

ER -